New Two-Step transplant shows promise for tough blood cancers
NCT ID NCT03032783
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a two-step donor stem cell transplant in 51 people with high-risk blood cancers. The approach uses total-body irradiation and chemotherapy to prepare the body, then infuses donor stem cells and later donor immune cells. The goal is to boost the anti-cancer effect while limiting severe side effects. The study looked at overall survival at two years and rates of graft failure and early death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor stem cells (with total-body irradiation, donor lymphocyte infusion, and cyclophosphamide)
What this could lead to
If successful, this approach could offer a safer way to perform donor stem cell transplants for people with high-risk blood cancers, potentially improving survival rates.
What could go wrong
This is a completed phase 2 trial with only 51 participants, so results are preliminary. The treatment carries risks like graft failure, severe infection, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadephia, Pennsylvania, 19107, United States